Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

ArriVent BioPharma, Inc. Common Stock

Healthcare US AVBP

32.82USD
3.04(10.21%)

Last update at 2026-06-04T15:45:00Z

Day Range

29.4933.00
LowHigh

52 Week Range

16.1032.14
LowHigh

Fundamentals

  • Previous Close 29.78
  • Market Cap1387.49M
  • Volume194046
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-4.32

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Income before tax -166.30800M -80.48800M -69.33300M -36.90600M -51.60600M
Minority interest - - - - -
Net income -166.30800M -80.48800M -69.33300M -36.90600M -51.60600M
Selling general administrative 24.18M 15.30M 9.71M 6.47M 3.02M
Selling and marketing expenses - - - - 0.75M
Gross profit - - - - -
Reconciled depreciation - - - - -
Ebit - -94.30800M - - -63.20066M
Ebitda -177.53400M -80.48800M - - -51.60600M
Depreciation and amortization - - - - 11.59M
Non operating income net other - - - - -
Operating income -177.53400M -94.30800M -74.59000M -36.90600M -8.69600M
Other operating expenses 177.53M 94.31M - - 8.70M
Interest expense - - - - -
Tax provision - - - - -
Interest income 11.23M 13.82M 5.26M 0.00000M -
Net interest income 11.23M 13.82M 5.26M 0.00000M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - -80.48800M - - -11.59466M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M -
Total operating expenses 177.53M 94.31M 74.59M 36.91M 8.70M
Cost of revenue - - - - -
Total other income expense net 11.23M 13.82M - - -42.91000M
Discontinued operations - - - - -
Net income from continuing ops -166.30800M -80.48800M -69.33300M -36.90600M -
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Total assets 333.17M 274.94M 163.10M 182.83M 43.04M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 20.08M 7.62M 8.58M 18.57M 5.39M
Total liab 25.95M 17.29M 316.29M 267.94M 1.82M
Total stockholder equity 307.22M 257.65M -153.19300M -85.10900M 41.22M
Deferred long term liab - - - - -
Other current liab 20.00M 13.33M - - -
Common stock 0.00400M 0.00300M - - -
Capital stock 0.00400M 0.00300M 0.00000M 0.00000M 89.86M
Retained earnings -404.64100M -238.33300M -157.84500M -88.51200M -51.60600M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 45.54M 74.29M 150.39M 163.37M 37.28M
Cash and equivalents - - - - -
Total current liabilities 25.95M 17.27M 11.62M 8.36M 1.82M
Current deferred revenue - - - - -
Net debt -45.52600M -74.11700M - - -
Short term debt 0.01M 0.16M - - -
Short long term debt - - - - -
Short long term debt total 0.01M 0.18M - - -
Other stockholder equity 711.85M 496.19M - - -
Property plant equipment - - - - -
Total current assets 332.90M 226.98M 159.97M 182.62M 42.95M
Long term investments 0.00000M 47.68M - - -
Net tangible assets - - - - -
Short term investments 267.28M 144.57M - - -
Net receivables - 0.50M - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 5.93M 3.78M 4.53M 3.09M 0.29M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.01M -0.21100M - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.26M 0.13M 0.11M 0.07M 0.09M
Deferred long term asset charges - - - - -
Non current assets total 0.27M 47.96M 3.13M 0.21M 0.09M
Capital lease obligations 0.01M 0.18M 0.32M 0.14M 0.00000M
Long term debt total - - - - -
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Investments -71.22800M -192.46500M 0.00000M 0.00000M -
Change to liabilities - - - - -
Total cashflows from investing activities -71.22800M -192.46500M - - -40.00000M
Net borrowings - - - - -
Total cash from financing activities 203.06M 186.58M 42.86M 169.72M 89.87M
Change to operating activities - - - - -
Net income -166.30800M -80.48800M -69.33300M -36.90600M -51.60600M
Change in cash -28.75300M -76.09600M -12.98300M 126.09M 37.28M
Begin period cash flow 74.29M 150.39M 163.37M 37.28M -
End period cash flow 45.54M 74.29M 150.39M 163.37M 37.28M
Total cash from operating activities -160.58800M -70.21200M -55.84200M -43.63100M -12.58700M
Issuance of capital stock 202.63M 185.95M 44.92M 169.71M -
Depreciation -3.02600M - - - -
Other cashflows from investing activities - - - - -40.00000M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - - -
Other cashflows from financing activities -0.07000M 0.63M - - 119.82M
Change to netincome - - - - -
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -3.77400M 7.07M 12.60M -7.14900M -3.94100M
Stock based compensation 12.52M 3.21M 0.90M 0.42M 0.07M
Other non cash items -3.02600M - - - 42.96M
Free cash flow -160.58800M -70.21200M -55.84200M -43.63100M -12.58700M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x)
AVBP
ArriVent BioPharma, Inc. Common Stock		 3.04 10.21% 32.82 - - - 4.52
NVO
Novo Nordisk A/S		 2.31 5.51% 44.31 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.23% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 14.76 3.44% 443.10 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.86 1.11% 625.81 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

ArriVent BioPharma, Inc. Common Stock

18 Campus Boulevard, Newtown Square, PA, United States, 19073

Key Executives

Name Title Year Born
Dr. Zhengbin Yao Ph.D. Co-Founder, Chairman, President & CEO 1966
Dr. Stuart Lutzker M.D., Ph.D. Co-Founder, President of Research & Development and Director 1961
Ms. Robin LaChapelle M.A. Co-Founder & COO 1973
Mr. Winston Kung M.B.A. CFO & Treasurer 1976
Ms. Yang Wang Ph.D. Chief Technology Officer NA
Mr. James Paul Kastenmayer J.D., Ph.D. General Counsel & Secretary 1972
Dr. Dandan Dong Chief Business Officer 1985
Ms. Meghna Chowdary Senior Vice President of Commercial Strategy NA
Dr. James Paul Kastenmayer J.D., Ph.D. General Counsel & Secretary 1972
Mr. Brent S. Rice Chief Commercial Officer 1966

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions